http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008105375-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 |
| filingDate | 2006-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008105375-A |
| titleOfInvention | LIPOLYTIC COMPOSITIONS WITH PROLONGED RELEASE FOR LOCAL TREATMENT OF FATAL TISSUE DEPOSIT |
| abstract | 1. The composition for injection into the deposits of adipose tissue, including! beta-2 selective long-acting adrenergic receptor agonist; ! a compound for reducing adipose tissue desensitization to a beta adrenergic receptor agonist; and! liquid carrier. ! 2. The composition according to claim 1, characterized in that the selective beta-2 adrenergic receptor agonist is lipophilic. ! 3. The composition according to claim 1, characterized in that the selective beta-2 adrenergic receptor agonist is selected from salmeterol, formoterol, their salts and their solvates. ! 4. The composition according to claim 1, characterized in that the compound for reducing desensitization of the target tissue to the beta-adrenergic receptor agonist is a glucocorticosteroid. ! 5. The composition according to claim 1, characterized in that the compound for reducing desensitization of the target tissue to the beta-adrenergic receptor agonist is an antihistamine compound. ! 6. The composition according to claim 1, characterized in that the compound for reducing desensitization of the target tissue to the beta-adrenergic receptor agonist is a glucocorticosteroid and antihistamine. ! 7. The composition according to claim 1, characterized in that the compound for reducing desensitization of the target tissue to the beta-adrenergic receptor agonist is at least one compound from dexamethasone, prednisolone, fluticasone propionate, budesonide, ketotifen and their analogues. ! 8. The composition according to claim 1, characterized in that the liquid carrier is a lipophilic liquid carrier. ! 9. The composition according to claim 1, characterized in that at least one of the selective long-acting beta-2 adrenergic receptor agonists |
| priorityDate | 2005-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.